Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.67 |
| ▸ | LMNA | P02545 | 3/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | LDHA | P00338 | 1/20 | 0.57 |
| ▸ | LDHB | P07195 | 1/20 | 0.57 |
| ▸ | HAO1 | Q9UJM8 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | STAT1 | P42224 | 1/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 4/20 | 0.50 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL396870 | 0.89 | ALDH1A1 (0.80) | KDM4EALDH1A1LMNATDP1LDHA | |
| SCHEMBL12177745 | 0.82 | ALDH1A1 (0.69) | KDM4EALDH1A1LMNATDP1LDHA | |
| SCHEMBL2325829 | 0.80 | KDM4E (1.00) | KDM4EALDH1A1LMNATDP1LDHA | |
| SCHEMBL397009 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1LMNATDP1LDHA | |
| SCHEMBL2318474 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1LMNATDP1LDHA | |
| SCHEMBL1143469 | 0.80 | KDM4E (0.67) | KDM4EALDH1A1LMNATDP1LDHA | |
| SCHEMBL398700 | 0.80 | ALDH1A1 (0.67) | KDM4EALDH1A1LMNATDP1LDHA | |
| SCHEMBL2557746 | 0.79 | KDM4E (1.00) | KDM4EALDH1A1LMNATDP1LDHA | |
| SCHEMBL5231710 | 0.79 | ALDH1A1 (0.61) | KDM4EALDH1A1LMNATDP1LDHA | |
| SCHEMBL622653 | 0.79 | KDM4E (0.66) | KDM4EALDH1A1LMNATDP1LDHA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121537365-A | Preparation method and detection method of high-sensitivity fluorescent probe for detecting cysteine | 海南大学 | 2026-02-17 | — | — | CN | disclosed |
| CN-119330967-B | MET transcription inhibitor and preparation method and application thereof | 中国药科大学 | 2025-04-25 | — | — | CN | disclosed |
| CN-119330967-A | MET transcription inhibitor and preparation method and application thereof | 中国药科大学 | 2025-01-21 | — | — | CN | disclosed |
| US-7241763-B2 | 3-furanyl analogs of toxoflavine as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-07-10 | — | — | US | disclosed |
| EP-1523485-B1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2007-02-14 | — | — | EP | disclosed |
| US-20060040943-A1 | 3-Furanyl analogs of toxoflavine as kinase inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-23 | — | — | US | disclosed |
| EP-1523485-A1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-20 | — | — | EP | disclosed |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | TRIAD THERAPEUTICS, INC. | 2005-02-24 | — | — | US | disclosed |
| WO-2004007499-A1 | 3-FURANYL ANALOGS OF TOXOFLAVINE AS KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-01-22 | — | — | WO | disclosed |
| US-20040009526-A1 | Common ligand mimics: thiazolidinediones and rhodanines | YU LIN (US) | 2004-01-15 | — | — | US | disclosed |
| WO-2003072033-A2 | COMMON LIGAND MIMICS: THIAZOLIDINEDIONES AND RHODANINES | TRIAD THERAPEUTICS, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009526-A1 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | KDM4E 4288/4885ALDH1A1 1216/4885LMNA 4805/4885 |
| US-20060040943-A1 | 3-Furanyl analogs of toxoflavine as kinase inhibitors | GRK3, GRK4, GRK6 | KDM4E 1876/4885ALDH1A1 4096/4885LMNA 2359/4885 |
| US-20050042674-A9 | Common ligand mimics: thiazolidinediones and rhodanines | GPR65, NR2E3, FGFR3 | KDM4E 4288/4885ALDH1A1 1216/4885LMNA 4805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.